A Phase IV, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of 100 mg SC Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Are Inadequately Controlled With Standard Treatment

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) without concomitant use of Intranasal corticosteroids (INCS) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Start Date20 Jul 2026

Sponsor / Collaborator

GSK Plc

JPRN-jRCT2031260158

/ RecruitingPhase 4

A Ph IV, single-arm, open-label study to evaluate the efficacy and safety of 100 mg SC depemokimab monotherapy without concomitant use of intranasal corticosteroids (INCS) in Japanese participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who are inadequately controlled with standard treatment

Start Date19 Jul 2026

Sponsor / Collaborator

GlaxoSmithKline KK

NCT07671001

/ Not yet recruitingPhase 3

A Phase 3, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Depemokimab (GSK3511294) Administered Subcutaneously as Add on Maintenance Treatment of Asthma With Type 2 Inflammation Characterised by an Eosinophilic Phenotype in Participants Aged 6 to 11 Years Old

This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.

Start Date26 Jun 2026

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Depemokimab

100 Translational Medicine associated with Depemokimab

100 Patents (Medical) associated with Depemokimab

Literatures (Medical) associated with Depemokimab

01 Sep 2026·PULMONARY PHARMACOLOGY & THERAPEUTICS

The preclinical discovery and development of depemokimab for severe eosinophilic asthma

Review

Author: Pagliaro, Raffaella ; Patella, Vincenzo ; Rogliani, Paola ; Cazzola, Mario ; Matera, Maria Gabriella ; Bianco, Andrea

Severe eosinophilic asthma is driven by interleukin (IL)-5-mediated type 2 inflammation and frequently requires long-term biologic therapy. Depemokimab was designed to achieve sustained IL-5 neutralization with a twice-yearly dosing schedule, addressing key unmet needs related to treatment burden and adherence. This review summarizes the molecular design, preclinical pharmacology, model-informed drug development (MIDD) strategy, Phase I-III clinical trial program, and regulatory approvals of depemokimab in asthma and chronic rhinosinusitis with nasal polyps. Depemokimab exemplifies how rational antibody engineering, including Fc modification and high-affinity IL-5 binding, can enable sustained pharmacodynamic activity and ultra-long-acting cytokine inhibition. A twice-yearly dosing regimen may offer advantages in terms of treatment adherence, patient convenience, and long-term disease control. The application of MIDD approaches facilitated efficient clinical development and supported the progression of pivotal trials, potentially shortening development timelines by approximately two to three years. Although efficacy and safety data are encouraging, longer-term real-world evidence will be necessary to better define immunogenicity, rare adverse events, and adherence patterns. Comparative effectiveness studies of depemokimab versus other approved anti-IL-5 therapies and type 2-targeted biologics will be critical to establish its relative clinical value. Further investigation into additional eosinophilic diseases, pediatric populations, and diverse healthcare settings may expand its therapeutic utility, positioning depemokimab as a representative example of next-generation long-acting biologics that target cytokine-mediated inflammatory diseases.

01 Jul 2026·Journal of Allergy and Clinical Immunology-In Practice

The Management of NSAID-ERD Patients in the Current Treatment Landscape: Aspirin Desensitization, Biologics, Both, or Neither?

Review

Author: Bobolea, Irina ; Pfaar, Oliver ; White, Andrew A ; Mullol, Joaquim ; Laidlaw, Tanya M ; Celik, Gulfem Elif ; Stevens, Whitney W

The management of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease has undergone a fundamental shift over the past decade with the emergence of respiratory biologics. Characterized by the clinical triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and hypersensitivity to cyclo-oxygenase-1 inhibition, the disease is marked by aggressive type 2 inflammation and eicosanoid dysregulation. This review evaluates the strategic balance between aspirin therapy after desensitization (ATAD) and targeted biologics in the modern treatment landscape. Although ATAD remains a high-value, cost-effective, disease-modifying intervention, its clinical success is often contingent on comprehensive surgical debulking and strict daily adherence. Conversely, the existing respiratory biologics available for the treatment of CRSwNP, including dupilumab, omalizumab, mepolizumab, tezepelumab, and, in Europe, depemokimab, offer potent, nonsurgical alternatives that target specific inflammatory pathways. Despite these clinical gains, the high financial cost of biologics remains a barrier compared with the pharmacoeconomic superiority of postoperative ATAD. For refractory cases, combination therapy or a stepwise strategy may be necessary. Ultimately, a multidisciplinary, individualized approach is essential to optimize outcomes in this complex patient population.

01 Jun 2026·DRUGS

Depemokimab: First Approval

Review

Author: Lee, Arnold

Depemokimab (depemokimab-ulaa; EXDENSUR) is an anti-IL-5 antibody being developed by GSK for the treatment of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Add-on treatment with depemokimab reduced asthma-related exacerbations in patients with severe asthma with an eosinophilic phenotype, in addition to reducing the severity of nasal polyps and nasal obstruction in patients with CRSwNP. This article summarizes the milestones in the development of depemokimab leading to this first approval in the UK as an add-on maintenance treatment of asthma in adult and adolescent patients aged ≥ 12 years with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids plus another asthma controller; and as add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.

News (Medical) associated with Depemokimab

17 Jun 2026

·www.biospace.com

Exdensur (depemokimab injection) approved in Canada for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps

Exdensur is the first and only long-acting biologic with twice-yearly dosing approved in Canada for severe asthma characterized by an eosinophilic phenotype and chronic rhinosinusitis with nasal polyps (CRSwNP). In Canada, approximately half of people living with asthma remain uncontrolled, with asthma attacks leading to more than 80,000 emergency room visits annually, while an estimated hundreds of thousands are affected by CRSwNP Approval is based on data from the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen for depemokimab versus placebo. Phase III trials showed Exdensur reduced asthma exacerbations, including those requiring hospitalization and/or emergency department visits and improved nasal polyp size and obstruction for CRSwNP patients. MISSISSAUGA, ON , June 2, 2026 /CNW/ - GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications: As an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma characterized by an eosinophilic phenotype and inadequately controlled by medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller. As an add-on maintenance treatment with intranasal corticosteroids in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery. The approval is based on data from the positive SWIFT and ANCHOR phase III trials. In the SWIFT-1 and SWIFT-2 trials, depemokimab demonstrated a significant reduction in asthma exacerbation rate versus placebo in patients with severe asthma characterized by an eosinophilic phenotype. Depemokimab additionally reduced the number of asthma exacerbations requiring hospitalization and/or emergency department visits versus placebo. 1 In the ANCHOR-1 and ANCHOR-2 trials, depemokimab demonstrated significant reductions in nasal polyp size and nasal obstruction versus placebo in patients with chronic rhinosinusitis with nasal polyps. 2,3 Across the SWIFT and ANCHOR clinical trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo. 1,4 Michelle Horn, VP & Country Medical Director, GSK Canada, said : "Today's approval of Exdensur by Health Canada is a meaningful milestone for Canadian patients living with severe asthma and/or chronic rhinosinusitis with nasal polyps. With its unique long-acting pro twice-yearly dosing, Exdensur offers a differentiated treatment option that has the potential to improve disease management and patient outcomes, bringing innovative solutions to address unmet needs in respiratory diseases." Jeffrey Beach, President & CEO, Asthma Canada, said : "For Canadians struggling with severe asthma and CRSwNP, the approval of Exdensur is truly welcome news. This new treatment, with its unique dosing schedule, represents a meaningful innovation in how these conditions can be managed. While this approval is a vital first step, our priority remains advocating for timely and equitable access, so that this promising therapy can genuinely help to improve the lives of those who need it." In Canada, more than 4.7 million people are currently affected by asthma, a chronic and sometimes debilitating condition. 5 Many Canadian asthmatics continue to experience symptoms such as difficulty breathing and chest tightness, despite treatment with high-dose inhaled corticosteroids plus a second controller. 6,7 People with CRSwNP experience symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being. 8,9,10,11 The impact of CRSwNP on overall quality of life has been reported to be comparable with other chronic diseases such as COPD, asthma, and diabetes. 9 Depemokimab is a long-acting monoclonal antibody that targets human interleukin-5 (IL-5), a key cytokine (protein) involved in eosinophilic inflammation, which is an underlying driver in many diseases present in the majority of patients with difficult-to-treat asthma and up to 85% of people with CRSwNP. 8,9,10,11,12 Exdensur 's extended half-life, high-binding affinity and specificity support its dosing regimen of one injection every six months (26 weeks). 1,2,3 About the SWIFT phase III trials The SWIFT-1 and SWIFT-2 clinical trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 participants with severe asthma who were randomized to receive depemokimab or a placebo respectively, in addition to their standard of care (SOC) treatment with medium to high-dose inhaled corticosteroids plus at least one additional controller. The full analysis set in SWIFT-1 included 250 patients in the depemokimab plus SOC arm and 132 in the placebo plus SOC arm; in SWIFT-2, 252 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm. 1 Results from the SWIFT trials were presented at the 2024 European Respiratory Society International Conference and published in the New England Journal of Medicine . 1,15 About the ANCHOR phase III trials ANCHOR-1 included 143 patients in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm; in ANCHOR-2, 129 patients were included in the depemokimab plus SOC arm and 128 in the placebo plus SOC arm. All 528 patients had inadequately controlled CRSwNP, including nasal polyps in both nasal cavities (an endoscopic bilateral NPS ≥5), and had either undergone previous surgery for CRSwNP, had received previous treatment with systemic corticosteroids (SCS) or were intolerant to SCS. Patients received depemokimab or placebo at six-monthly intervals (26 weeks) in addition to SOC (maintenance intranasal corticosteroids). 2 Results from the ANCHOR trials were presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and published in The Lancet . 4,16 About severe asthma Severe asthma is defined as asthma that requires treatment with medium- to high-dose inhaled corticosteroids plus a second therapy (i.e., systemic corticosteroid or biologic) to prevent it from becoming uncontrolled, or which remains uncontrolled despite therapy. 13 Type 2 inflammation is the underlying pathology in more than 80% of patients with severe asthma, in which patients exhibit elevated levels of eosinophils (a type of white blood cell). 13 About CRSwNP CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps. 9,12 People with CRSwNP experience debilitating symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections and nasal discharge that can significantly affect their emotional and physical well-being. 9,12 Similar to asthma, the majority of cases of CRSwNP (85%) are driven by chronic type 2 inflammation, which is strongly associated with comorbidities, more severe disease, recurring symptoms and tissue remodelling. 8,9,10,11,12,14 About Exdensur (depemokimab) Exdensur is the first and only long-acting biologic being developed for certain inflammatory diseases characterized by raised eosinophils. It combines high interleukin-5 (IL-5) binding affinity and high specificity with an extended half-life to enable twice-yearly dosing. 1,4 Please consult the Exdensur product monograph at for complete safety information. The product monograph is also available by calling 1-800-387-7374. About GSK in Respiratory GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next-generation standard of care and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less-understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim of modifying the underlying disease dysfunction and preventing progression. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026. References 1. Jackson DJ, et al. Six Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype. NEJM. Published on September 9 at NEJM.org. 2. ClinicalTrials.gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-1) Available at: Accessed February 2025. 3. ClinicalTrials.gov. Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) Available at: Accessed February 2025. 4. Gevaert P, et al. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase III, randomised, double-blind, parallel trials. The Lancet. Published on February 28 at thelancet.com. 5. Public Health Agency of Canada. (2024). Canadian Chronic Disease Surveillance System (CCDSS) Data Tool. Retrieved from 6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Available at: Accessed February 2025. 7. World Health Organisation. Asthma Key Facts. Available at: Accessed February 2025. 8. Laidlaw TM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J. Allergy Clin. Immunol. 2001;9(3):1133-1141. 9. Bachert C, et al. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021;b 11;14:127-134. 10. De Corso E, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review. Acta Otorhinolaryngol Ital. 2023;43 (Suppl. 1):S3-S13. 11. Chen S, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911. 12. Bachert C, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29-36. 13. Heaney L, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814-830. 14. Bernstein JA. Use of patient-reported outcome measures and inflammatory biomarkers to differentiate chronic rhinosinusitis with nasal polyp endotypes: Is it feasible? Ann Allergy Asthma Immunol. 2023 Apr;130(4):409-410. doi: 10.1016/j.anai.2023.01.004. PMID: 37005049. 15. Jackson, D, et al. "Late breaking abstract - depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: The phase IIIA randomised SWIFT-1/2 studies." European Respiratory Journal 2024, vol. 64, no. 68, 14 Sept. 2024, 16. Han, J, et al. Efficacy and Safety of Twice-Yearly Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Phase III Randomized, Double-Blind, Placebo-Controlled Replicate ANCHOR-1/2 Trials. Journal of Allergy and Clinical Immunology , Volume 155, Issue 2, AB443. SOURCE GlaxoSmithKline Inc.

Phase 3Clinical ResultDrug Approval

29 Apr 2026

·www.fiercepharma.com

New GSK CEO’s first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial

In Luke Miels' first quarter as CEO, GSK's Q1 revenue of £7.6 billion marked a 5% increase year over year at constant exchange rates. In GSK’s first quarter under Luke Miels as CEO, the company’s flagship shingles vaccine, Shingrix, set a new quarterly sales record, while its closely watched asthma launch, Exdensur, showed “early signals” of commercial progress despite a recent trial flop.Sales of Shingrix in the U.S. bounced back from a 17% decline in full-year 2025 to reach 12% growth in the first quarter at constant exchange rates, fueled by inventory build related to the launch of a new, easier-to-use prefilled syringe.A boost from the U.S. market, plus strong demand in Europe, lifted Shingrix’s global Q1 sales to 1.03 billion pound sterling ($1.39 billion), setting a new quarterly record, Nina Mojas, GSK’s president, global products strategy, said Wednesday on an investor call.As the entire vaccine industry grapples with a hostile U.S. policy environment, Shingrix’s surge comes as a surprise. The turnover beat Wall Street’s expectations by 20%.In the U.S., cumulative immunizations for shingles grew 3.5 percentage points year over year and reached 45% among eligible adults, according to Miels.“If you look at the remaining effort, there’s about 70 million people above 50 who remain unvaccinated. About a third of them have intent to get vaccinated,” Miels said on the call, citing market research. “We’re concentrating on the comorbid subpopulation that are more motivated, and their doctors and pharmacists are more motivated to do that.” Meanwhile, demand in China also appears to be improving as the number of administered doses increases, although this dynamic is not being reflected in GSK’s sales numbers for at least the majority of the year because the doses are coming from existing stockpiles at its partner, Chongqing Zhifei Biological Products, Mojas said. The market for self-paid vaccines has shrunk in China in recent years, impacting major products such as Shingrix and Merck & Co.’s HPV blockbuster Gardasil, which is also distributed by Zhifei.For the rest of the year, however, Mojas cautioned about difficult year-over-year comparisons for the vaccine in Europe and Japan.“Further penetration opportunities remain with around 11% of the eligible population immunized in our top 10 markets outside the U.S.,” she said.While Shingrix drove GSK’s Q1 sales growth, numbers from the respiratory syncytial virus vaccine Arexvy do not look so rosy. The shot’s sales dropped 18% to 65 million pounds sterling with low out-of-season uptake, missing analysts’ consensus by 13%, as U.S. sales continued to decline amid slower market demand. Launch progress On Wednesday’s call, GSK’s management touted the launch momentum of several newer products. Among them, twice-yearly IL-5 drug Exdensur is one of the most important rollouts, with its peak annual sales estimated at about 3 billion pounds sterling by GSK across several respiratory diseases. Approved by the FDA to treat severe asthma in December, Exdensur only brought in 11 million pounds sterling in Q1 sales. Mojas noted that access to the drug in the U.S. is currently limited to about 20% of commercial patients ahead of the assignment of a permanent J-code for reimbursement, which is expected in July. “Unaided awareness is ahead of benchmarks and intent to use is nicely at benchmark,” Miels said of Exdensur. “And the main driver is questions around access, which is what we expect, particularly when you’re buying a six-monthly treatment.”To convince investors that Exdensur and its long-acting dosing represent “a key value driver,” Mojas noted that 65% of patients discontinued their short-acting biologic in the first 12 months. In its early launch days, about 70% of Exdensur users are coming from other biologics, she noted. Biologic compliance is a main reason for discontinuation, as some patients end up switching back to inhaled medicines, Mojas said. However, GSK recently hit a snag with its plan to convince patients that they can switch from an existing short-acting biologics to Exdensur with similar benefits. The phase 3a Nimble trial, which compared Exdensur with GSK’s own monthly Nucala or AstraZeneca’s bimonthly Fasenra, failed to meet statistical non-inferiority. Annualized rates of clinically significant exacerbations over 52 weeks were 0.57 with the GSK drug, versus 0.49 for the comparator arm. While the rate ratio was 1.16, the upper bound of the 95% confidence interval reached 1.38, which exceeded the predefined non-inferiority bar of 1.28, leading the trial to miss its main endpoint. Because Nimble was a well-controlled study, the general exacerbation rate was low, GSK’s R&D chief Tony Wood, Ph.D., said on the earnings call. The absolute difference in annual exacerbation rates was 0.08 between the two arms, meaning that a patient on therapy would need 12.5 years to realize a single additional exacerbation, he noted.“You put that into the context of the beneficial compliance that’s associated with the longer-acting agent, I think you have the importance of [Exdensur] as a long-acting agent in that population,” Wood said.In a well-controlled study, patients are closely followed and treatment adherence is typically better compared with real-world experience. Mojas also pointed out that about 30% of asthma patients are taking a biologic. She suggested that Exdensur could capture some of the biologic-naïve patients with its convenience edge once it gets the J-code. Exdensur is undergoing three phase 3 trials—Endura-1, -2 and Vigilant—in moderate to severe chronic obstructive pulmonary disease, an indication that fueled Nucala’s 12% growth at constant exchange rates to 484 million pound sterling in Q1. All told, GSK’s Q1 haul of 7.6 billion marked a 5% increase year over year at constant currencies, meeting analysts’ consensus. The British pharma affirmed its full-year 2026 guidance, including sales increase of between 3% to 5%.

Phase 3Clinical ResultVaccineDrug ApprovalExecutive Change

29 Apr 2026

·endpoints.news

GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts

GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with the media Wednesday. GSK announced in February it would lay off up to 350 R&D employees in the US and UK from a pool of 12,000 staffers. These cuts were announced while the company was busy intensely scrutinizing its pipeline, a process that Miels confirmed on Wednesday it is still focusing on. “We’re constantly evolving our resource allocation, so we want to move resources, people, expenditure and capital to where the growth is,” Miels said. “We’ve got a series of readouts coming and when we see them, we’ll move resources where there’s success, or we’ll rapidly redeploy where there’s not.” GSK is waiting on pivotal results from camlipixant in chronic cough, Jemperli in rectal cancer, Exdensur in eosinophilic granulomatosis with polyangiitis, and thrice-yearly Apretude PrEP for HIV. Jefferies analysts said camlipixant, a P2X3 receptor antagonist, could hit peak sales of $1.2 billion in the US. Exdensur, which secured its first US approval for severe asthma in December, is expected to hit $4 billion at its peak, according to GSK. The company also sees Jemperli pulling over $2.7 billion for monotherapy indications. GSK on Wednesday unveiled several changes in its pipeline. It is no longer developing a STING agonist ADC called XMT-2056. That Phase 1 asset featured in its $1.36 billion biobuck deal with Mersana Therapeutics in 2022. GSK also paused work on an mRNA vaccine for bird flu called GSK5536522, which was in Phase 2 development. In Phase 1, it dropped a TLR8 antagonist known as GSK5251738 for HBV infection. GSK told Endpoints News it could not disclose the specific reasons for each decision. The company’s Q1 sales increased 5% at constant exchange rates to £7.6 billion ($10.3 billion) in line with Wall Street expectations. Its general medicines sales of £2.3 billion fell just short of consensus, however, with strong vaccine performance softening the blow, Jefferies analysts wrote the same day. Q1 vaccine sales totaled £2.1 billion, up 4% from the same period last year. Editor’s Note: This article was updated to add context on GSK’s pipeline changes.

VaccinePhase 2Phase 1Clinical ResultmRNA

100 Deals associated with Depemokimab

External Link

KEGG	Wiki	ATC	Drug Bank
D12169	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eosinophilic Asthma	China	GlaxoSmithKline Trading Services Ltd.	25 Mar 2026
Severe asthma	United States	GlaxoSmithKline LLC	16 Dec 2025
Asthma	United Kingdom	GSK Plc	15 Dec 2025
Chronic rhinosinusitis with nasal polyps	United Kingdom	GSK Plc	15 Dec 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Phase 3	United States	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	China	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Japan	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Australia	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Bulgaria	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Canada	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Germany	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Greece	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	Israel	GSK Plc	20 Oct 2025
Bronchitis, Chronic	Phase 3	New Zealand	GSK Plc	20 Oct 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05602025 (CTgov)	Phase 1	Asthma	140	Depemokimab (Depemokimab Via SSD)	ncxeygrkwx(qkkikwfhhh) = jcbkvkxrys qqbvxfvhcp (ihdfdkhvom, 24.17) View more	-	16 Jun 2026
				Depemokimab (Depemokimab Via Autoinjector)	ncxeygrkwx(qkkikwfhhh) = gcjiwxomaq qqbvxfvhcp (ihdfdkhvom, 23.29) View more
NCT05140200 (CTgov)	Phase 1	Asthma	20	Depemokimab (Depemokimab 100mg)	gxwtqxsufu(ykapsfliqn) = ctqpyldrfk jggzjxinne (hflfjgnnvj, zxlbklwias - qcxwymsyen) View more	-	26 May 2026
				Depemokimab (Depemokimab 300mg)	gxwtqxsufu(ykapsfliqn) = wsksxajqjs jggzjxinne (hflfjgnnvj, wnbkfgbbmq - aieyfnckde) View more
NCT04718389 (NIMBLE, CTgov)	Phase 3	Asthma	1,717	Pre-filled Syringes (PFS)+GSK3511294 (Depemokimab) (Depemokimab 100mg SC)	dsdgfbiqck(pdzjcujvsw) = ptacyyymfa ttxrnyvkfg (thnoaohmnb, nbacpfoqrq - rtssyktzab) View more	-	18 May 2026
				Pre-filled Syringes (PFS)+Mepolizumab+Benralizumab (Mepolizumab 100 mg / Benralizumab 30 mg SC)	dsdgfbiqck(pdzjcujvsw) = gwhxxpsxym ttxrnyvkfg (thnoaohmnb, phmqthzwhe - fkwdkznrbu) View more
NCT05243680 (AGILE, AAAAI2026)	Phase 3	Asthma	629	Depemokimab (Prior Depemokimab)	yvxlyyuoqf(btrlsrxkac) = ucnhpcrvlp kwdkedvabb (fzkpbgfzht ) View more	Positive	27 Feb 2026
				Depemokimab (Prior Placebo)	yvxlyyuoqf(btrlsrxkac) = ifmxakecnx kwdkedvabb (fzkpbgfzht ) View more
NCT05274750 (ANCHOR-1, AAAAI2026)	Phase 3	Chronic rhinosinusitis with nasal polyps	154	Depemokimab 100mg	rgrvaexkka(iofwtnqkjv) = gzrtwriuhn hipozbjzxb (jmuxllwmey, 0.18) View more	Positive	27 Feb 2026
				Placebo	rgrvaexkka(iofwtnqkjv) = kesoizngis hipozbjzxb (jmuxllwmey, 0.19) View more
NCT05243680 (AGILE, CTgov)	Phase 3	Asthma	641	Placebo+GSK3511294 (Placebo in Previous Studies/GSK3511294 100 mg SC in Extension Study)	yukxnxmjxc = ooqtulfptp kcwcmmieyg (gufqmpednb, ocssbmffdo - rignxmzdoj) View more	-	15 Jan 2026
				GSK3511294 (GSK3511294 in Previous Studies/GSK3511294 100 mg SC in Extension Study)	yukxnxmjxc = glnhljuyus kcwcmmieyg (gufqmpednb, bwbwndeazk - kbtviwttgl) View more
NCT05274750 (ANCHOR-1, CTgov)	Phase 3	Chronic rhinosinusitis with nasal polyps	276	Depemokimab (GSK3511294) (Depemokimab)	rwuimsgtjc(smlpzvdydm) = dsfseiiamb ktkaqeqylf (sncumefqlo, 0.14) View more	-	03 Dec 2025
				Placebo (Placebo)	rwuimsgtjc(smlpzvdydm) = ioxwskcmac ktkaqeqylf (sncumefqlo, 0.15) View more
NCT05281523 (ANCHOR-2, CTgov)	Phase 3	Chronic rhinosinusitis with nasal polyps	264	Depemokimab (GSK3511294) (Depemokimab)	syoixnxduo(vrqavfbakj) = ixtlixkfxg zdtweltdbp (bbhciyzavi, 0.14) View more	-	09 Sep 2025
				Placebo (Placebo)	syoixnxduo(vrqavfbakj) = gzoqhnbigw zdtweltdbp (bbhciyzavi, 0.15) View more
NCT05281523 \| NCT05274750 (ANCHOR-1, Company_Website \| Literature) Manual	Phase 3	Chronic rhinosinusitis with nasal polyps	528	Depemokimab + SOC (ANCHOR-1)	hroznobgla(tupspismcd) = kewaevvxov kvbnytdbvz (ghzjpxwzsa ) Met View more	Positive	01 Mar 2025
				Placebo + SOC (ANCHOR-1)	rjeyjxmzop(lrmqbyalpb) = wltialpmxn ivgqxxlnkl (fbmgwobbok )
NCT04719832 (SWIFT-1, CTgov)	Phase 3	Asthma	395	Placebo (Placebo)	liftvnffwd(hhpfwfzjnr) = wfnjubqmkx iffgzdrnrv (svhgqzypcy, bgakfadluh - rrspxthsuw) View more	-	17 Dec 2024
				GSK3511294 (Depemokimab) (GSK3511294)	liftvnffwd(hhpfwfzjnr) = guoygatcew iffgzdrnrv (svhgqzypcy, vngjslmhpf - rxugrmmjey) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis